lanthanum carbonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4585	587-26-8

Description:

Molecule	Description
Synonyms: lanthanum carbonate fosrenol	a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease Molecular weight: 457.84 Formula: C3La2O9 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 63.19 ALOGS: ROTB: None

Molecule

Description

Synonyms:

lanthanum carbonate
fosrenol

a phosphate binder used for hyperphosphatemia treatment in end-stage renal disease

Molecular weight: 457.84
Formula: C3La2O9
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 63.19
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
2.25	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 16, 2008	PMDA	Bayer Yakuhin
Oct. 26, 2004	FDA	SHIRE LLC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	340.88	23.89	51	2735	489	63485747
Shunt occlusion	249.24	23.89	40	2746	625	63485611
Nephrogenic systemic fibrosis	125.73	23.89	31	2755	4525	63481711
Blood phosphorus increased	79.73	23.89	20	2766	3125	63483111
Peritonitis	74.14	23.89	28	2758	17126	63469110
Skin induration	69.43	23.89	18	2768	3205	63483031
Blood parathyroid hormone increased	51.33	23.89	14	2772	3024	63483212
Skin hypertrophy	49.80	23.89	14	2772	3377	63482859
Skin tightness	46.47	23.89	14	2772	4302	63481934
Peripheral arterial occlusive disease	42.54	23.89	13	2773	4188	63482048

Showing 1 to 10 of 22 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	487.90	22.87	144	7290	8457	34941040
Shunt stenosis	427.07	22.87	82	7352	700	34948797
Appendicitis	426.39	22.87	148	7286	14659	34934838
Cardiogenic shock	335.51	22.87	146	7288	26472	34923025
Stress	323.43	22.87	148	7286	30199	34919298
Shunt occlusion	270.03	22.87	57	7377	813	34948684
Ascites	266.16	22.87	149	7285	46422	34903075
Abdominal distension	257.47	22.87	158	7276	58334	34891163
Ventricular fibrillation	244.56	22.87	112	7322	22842	34926655
Multiple organ dysfunction syndrome	198.34	22.87	149	7285	76417	34873080

Showing 1 to 10 of 54 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	756.48	20.85	133	9446	1258	79733551
Appendicolith	564.94	20.85	143	9436	8408	79726401
Shunt occlusion	494.56	20.85	94	9485	1410	79733399
Appendicitis	463.82	20.85	149	9430	20645	79714164
Cardiogenic shock	351.70	20.85	146	9433	41768	79693041
Ascites	278.04	20.85	149	9430	75413	79659396
Ventricular fibrillation	273.76	20.85	113	9466	31813	79702996
Stress	270.74	20.85	149	9430	79463	79655346
Abdominal distension	233.82	20.85	157	9422	119493	79615316
Multiple organ dysfunction syndrome	207.10	20.85	146	9433	120100	79614709

Showing 1 to 10 of 76 entries

Previous1 2 3 4 5…8Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	V03AE03	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Drugs for treatment of hyperkalemia and hyperphosphatemia

Showing 1 to 1 of 1 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Renal Osteodystrophy with Hyperphosphatemia	indication
Hyperphosphatemia associated with administration of FGFR inhibitor	indication
Constipation	contraindication	14760008	DOID:2089
Fecal impaction	contraindication	44635007
Intestinal obstruction	contraindication	81060008	DOID:8437
Gastrointestinal obstruction	contraindication	126765001

Showing 1 to 6 of 6 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 1GM BASE	FOSRENOL	TAKEDA PHARMS USA	N021468	Nov. 23, 2005	RX	TABLET, CHEWABLE	ORAL	7381428	Aug. 26, 2024	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 250MG BASE	FOSRENOL	TAKEDA PHARMS USA	N021468	Oct. 26, 2004	DISCN	TABLET, CHEWABLE	ORAL	7381428	Aug. 26, 2024	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 500MG BASE	FOSRENOL	TAKEDA PHARMS USA	N021468	Oct. 26, 2004	RX	TABLET, CHEWABLE	ORAL	7381428	Aug. 26, 2024	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
EQ 750MG BASE	FOSRENOL	TAKEDA PHARMS USA	N021468	Nov. 23, 2005	RX	TABLET, CHEWABLE	ORAL	7381428	Aug. 26, 2024	REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
008767	NDDF
168924	PUBCHEM_CID
18979	MMSL
234416	RXNORM
35731	MMSL
4021512	VUID
4021512	VANDF
414570008	SNOMEDCT_US
414571007	SNOMEDCT_US
490D9F069T	UNII

Showing 1 to 10 of 19 entries

Previous1 2Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-252	TABLET, CHEWABLE	500 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-252	TABLET, CHEWABLE	500 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-253	TABLET, CHEWABLE	750 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-253	TABLET, CHEWABLE	750 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-254	TABLET, CHEWABLE	1000 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-254	TABLET, CHEWABLE	1000 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-256	POWDER	750 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-256	POWDER	750 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-257	POWDER	1000 mg	ORAL	NDA	31 sections
Fosrenol	HUMAN PRESCRIPTION DRUG LABEL	1	54092-257	POWDER	1000 mg	ORAL	NDA	31 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next